Assessment of biliary excretion of piperacillin-tazobactam in humans
- 1 August 1997
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 41 (8) , 1636-1640
- https://doi.org/10.1128/aac.41.8.1636
Abstract
Piperacillin-tazobactam concentrations in serum and bile were measured intraoperatively in 10 patients undergoing cholecystectomy (group 1) and 5 cholecystectomized patients provided with external bile duct drainage (group 2). Each patient received a single intravenous dose of piperacillin at 4 g plus tazobactam at 0.5 g over 30 min. Drug concentrations in both serum and bile were measured by high-performance liquid chromatography. In group 1 patients, serum and bile specimens and gallbladder wall fragments were collected at mean times of 70 and 83 min postinfusion, respectively. The mean concentrations of piperacillin and tazobactam were, respectively, 69.1 +/- 41.5 (standard deviation) and 9.9 +/- 5.1 microg/ml in serum, 630.4 microg/ml (range, 24.8 to 1,194 microg/ml) and 11.8 microg/ml (range, 3.6 to 22 microg/ml) in choledochal bile, 342.3 microg/ml (range, 1.1 to 1,149 microg/ml) and 7.7 microg/ml, (range, 0.2 to 23.1 microg/ml) in gallbladder bile, and 49.3 microg/g (range, 9.7 to 223 microg/g) and 2.9 microg/g (range, 0.1 to 5.9 microg/g) in the gallbladder wall. In group 2 patients, the amounts of drugs recovered in bile drainage obtained over 12 h were 28.4 +/- 18.0 and 1.0 +/- 0.5 mg for piperacillin and tazobactam, respectively. Peak piperacillin and tazobactam concentrations in bile reached 358 +/- 242 and 10.8 +/- 4.2 microg/ml, respectively. Comparison of drug levels in serum and bile suggests an underlying active secretion process for piperacillin elimination into the bile, unlike that of tazobactam. From a therapeutic viewpoint, given the concentrations of tazobactam recorded in bile fluid and tissue, the addition of this beta-lactamase inhibitor to piperacillin therapy might be of interest in the management of biliary tract infections, mostly in patients at risk of mixed aerobic-anaerobic infections due to beta-lactamase-producing organisms.Keywords
This publication has 21 references indexed in Scilit:
- Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamasesAntimicrobial Agents and Chemotherapy, 1994
- Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamaseAntimicrobial Agents and Chemotherapy, 1994
- Biliary excretion of cefixime: assessment in patients provided with T-tube drainageAntimicrobial Agents and Chemotherapy, 1993
- Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillinAntimicrobial Agents and Chemotherapy, 1991
- High-performance liquid chromatography of antibioticsJournal of Chromatography B: Biomedical Sciences and Applications, 1990
- Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilliAntimicrobial Agents and Chemotherapy, 1986
- Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamasesAntimicrobial Agents and Chemotherapy, 1986
- Uptake of benzylpenicillin, cefpiramide and cefazolin by freshly prepared rat hepatocytesBiochemical Pharmacology, 1986
- β-Lactam pharmacology in liver diseaseJournal of Antimicrobial Chemotherapy, 1983
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976